Susan Digiorgio-Gentile
Acute Care · Paramus, NJNPI 1689792210
Payments from drug & device makers
Across 75 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$387
- Braeburn Inc.$278
- Alkermes, Inc.$139
- Boston Scientific$117
- AbbVie$95
- Bayer$49
- plus $167 from 7 others
What the payments were for
- Food & beverage$1,233100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 22 | $387 |
| Braeburn Inc. | 20 | $278 |
| Alkermes, Inc. | 9 | $139 |
| Boston Scientific | 4 | $117 |
| AbbVie | 7 | $95 |
| Bayer | 2 | $49 |
| Lilly USA, LLC | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Novo Nordisk | 1 | $23 |
| Boehringer Ingelheim | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $13 |
How this compares
$1,233 in reported general payments places this provider in the 75th percentile of 656 acute care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 200 | $8,751 |
| EliquisApixaban | 13 | $7,778 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 23 | $5,259 |
| Buprenorphine Hcl | 24 | $675 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $565 |
| Hydroxyzine Pamoate | 21 | $315 |
| Atorvastatin Calcium | 18 | $268 |
| Duloxetine Hcl | 13 | $224 |
| Gabapentin | 27 | $218 |
| Lisinopril | 26 | $195 |
| Amlodipine Besylate | 43 | $193 |
| Pantoprazole Sodium | 21 | $181 |
| Naproxen | 24 | $181 |
| Levetiracetam | 13 | $181 |
| Alprazolam | 15 | $176 |
Paid to pharmacies, not to this prescriber.
Other acute care in Paramus
- Gabriella MagarelliHackensack$44K
- Per RosenkvistLivingston$29K
- Matthew OstroffPaterson$27K
- Ellen McCueNeptune$26K
- Suzanne ShuggLivingston$25K
- Maria Tedi CoronelHackensack$19K
- Hanane ChaibainouWestampton$16K
- Jennifer McCarthyNewark$16K
- Jennifer HarrarCamden$16K
- Vincent FroncekFlemington$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.